Story perspectives

FDA Approves Enbumyst: New Nasal Spray for Edema Relief

9/16/2025

47 4

Summary

Story summary

The FDA approved Corstasis Therapeutics' Enbumyst, a nasal spray for treating edema from CHF, CKD, and liver disease.
Enbumyst shows rapid absorption and effective diuretic response in clinical studies, offering a convenient outpatient option.
Corstasis plans to launch Enbumyst in Q4 2025, targeting healthcare professionals and outpatient clinics.
The company acquired patents for subcutaneous bumetanide formulations and aims for approval next year.
Corstasis competes with scPharmaceuticals, which recently received FDA approval for its CHF treatment device.

1 of 1

Story summary

The FDA approved Corstasis Therapeutics' Enbumyst, a nasal spray for treating edema from CHF, CKD, and liver disease.
Enbumyst shows rapid absorption and effective diuretic response in clinical studies, offering a convenient outpatient option.
Corstasis plans to launch Enbumyst in Q4 2025, targeting healthcare professionals and outpatient clinics.
The company acquired patents for subcutaneous bumetanide formulations and aims for approval next year.
Corstasis competes with scPharmaceuticals, which recently received FDA approval for its CHF treatment device.